APA (7th ed.) Citation

GF, H., CS, C., A, A., MIA, W., MM, A., YC, F., . . . CK, L. (2019). Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study. BMC cancer, 19(1), 896. https://doi.org/10.1186/s12885-019-6107-1

Chicago Style (17th ed.) Citation

GF, Ho, et al. "Real-world Experience of First-line Afatinib in Patients with EGFR-mutant Advanced NSCLC: A Multicenter Observational Study." BMC Cancer 19, no. 1 (2019): 896. https://doi.org/10.1186/s12885-019-6107-1.

MLA (9th ed.) Citation

GF, Ho, et al. "Real-world Experience of First-line Afatinib in Patients with EGFR-mutant Advanced NSCLC: A Multicenter Observational Study." BMC Cancer, vol. 19, no. 1, 2019, p. 896, https://doi.org/10.1186/s12885-019-6107-1.